Vertex Pharmaceuticals said Tuesday that treatment with a combination of three cystic fibrosis drugs resulted in a statistically significant improvement in lung function for patients enrolled in two pivotal clinical trials.
With these positive data, the Boston-based biotech takes a step closer towards its long-stated goal of marketing new therapies capable of treating 90 percent of the genetic mutations that cause cystic fibrosis.
A second pair of Phase 3 clinical trials testing a different triple combination will read out in the first quarter of next year, after which Vertex will choose the best option and submit a marketing application to regulators in the U.S. and Europe.
About the Author Reprints
